New schizophrenia drug MP-214 put to the test in 512-Patient trial

NCT ID NCT01625000

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested an experimental drug called MP-214 in 512 people with schizophrenia. Participants took either a daily dose of MP-214 (3, 6, or 9 mg), an existing antipsychotic (risperidone), or a placebo for six weeks. The main goal was to see if MP-214 reduces schizophrenia symptoms better than a placebo, using a standard symptom rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MP-214 (an experimental antipsychotic drug)
What this could lead to: If successful, MP-214 could offer a new treatment option for managing schizophrenia symptoms.
What could go wrong: This is an early-to-mid-stage trial; results may not confirm effectiveness or safety. Side effects are possible, and the drug may not outperform existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychiatric disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Study site

Sapporo, Hokkaido, Japan
Study site

Seoul, South Korea
Study site

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.